Telbivudine
- Generic Name
- Telbivudine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O5
- CAS Number
- 3424-98-4
- Unique Ingredient Identifier
- 2OC4HKD3SF
- Background
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
- Indication
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Lin Bingliang
- Target Recruit Count
- 300
- Registration Number
- NCT01799486
Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus
- Conditions
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Hua Zhang
- Target Recruit Count
- 700
- Registration Number
- NCT01788371
Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Beijing YouAn Hospital
- Target Recruit Count
- 700
- Registration Number
- NCT01743079
- Locations
- 🇨🇳
Beijing YouAn Hospital, Beijing, Beijing, China
Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Yi-Hua Zhou
- Target Recruit Count
- 335
- Registration Number
- NCT01637844
- Locations
- 🇨🇳
Taixing People's Hospital, Taixing, Jiangsu, China
🇨🇳Zhenjiang Fourth People's Hospital, Zhenjiang, Jiangsu, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT01595685
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT01588912
- Locations
- 🇰🇷
Byung Chul Yoon, Busan, Korea, Republic of
🇰🇷Eun Uk Jung, Busan, Korea, Republic of
🇰🇷Hyun Young Woo, Busan, Korea, Republic of
Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2011-11-29
- Lead Sponsor
- Cz Li
- Target Recruit Count
- 56
- Registration Number
- NCT01480492
- Locations
- 🇨🇳
Changhai Hospital, Shanghai, Shanghai, China
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- The Fifth People's Hospital of Suzhou
- Target Recruit Count
- 120
- Registration Number
- NCT01380951
- Locations
- 🇨🇳
the Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
- Conditions
- Interventions
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT01379508
- Locations
- 🇹🇷
Novartis Investigative Site, Trabzon, Turkey
Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B
- Conditions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 110
- Registration Number
- NCT01270165
- Locations
- 🇰🇷
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.